HER2-Low Breast Cancer: Molecular Characteristics and Prognosis
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Background: We aimed to determine the distribution of intrinsic subtypes within HER2-low breast cancer (BC), and to describe the prognostic impact of HER2-low status on survival outcomes. Methods: This is a retrospective, observational study of primary BC extracted from The Cancer Genome Atlas dataset. We described the distribution of PAM50 intrinsic subtypes within HER2-low BC subtype according to hormonal receptor status (positive (HR+) and negative (HR−)). Secondly, we assessed the impact of HER2-low on survival outcomes (progression-free interval (PFI), disease-free interval (DFI), and overall survival (OS)). Results: We analyzed 804 primary BCs, including 410 (51%) HER2-low BCs (336 HR+ and 74 HR−). The proportion of HER2-enriched tumors was higher in the HER2-low/HR− group compared to HER2-low/HR+ (13.7% versus 1.2%, respectively). HER2-enriched tumors were more frequent in HER2-low/HR− and HER2-low/HR+ subtypes, compared to HER2-negative/HR− and HER2-negative/HR+ subtypes, respectively (13.7% versus 1.6% and 1.2% versus 0.5%, respectively). We observed no significant differences in PFI, DFI, and OS between HER2-low subtypes and each non-HER2-low subtype paired by HR status. Conclusions: Our characterization of PAM50 intrinsic subtypes within HER2-low breast cancer may explain the different clinical behaviors and responses to treatment, and ultimately support further investigation of new treatment strategies in the HER2-low category. Moreover, it highlights the importance of considering HR status in the HER2-low category.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S., Voduc, D., Vickery, T., Davies, S., Fauron, C., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,721
TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data
Colaprico, A., Silva, T. C., Olsen, C., Garofano, L., Cava, C., Garolini, D., Sabedot, T. S., Malta, T. M., Pagnotta, S. M., Castiglioni, I., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1507 · Cited by 4,183
Liu, J., Lichtenberg, T., Hoadley, K. A., Poisson, L. M., Lazar, A. J., Cherniack, A. D., Kovatich, A. J., Benz, C. C., Levine, D. A., Lee, A. V., et al. (2018) · Cell · doi:10.1016/j.cell.2018.02.052 · Cited by 3,725
Wolff, A. C., Hammond, M. E. H., Hicks, D. G., Dowsett, M., McShane, L. M., Allison, K. H., Allred, D. C., Bartlett, J. M. S., Bilous, M., Fitzgibbons, P., et al. (2014) · Archives of Pathology and Laboratory Medicine · doi:10.5858/arpa.2013-0953-sa · Cited by 1,762
Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP Guideline update
Allison, K. H., Hammond, M. E. H., Dowsett, M., McKernin, S. E., Carey, L. A., Fitzgibbons, P. L., Hayes, D. F., Lakhani, S. R., Chavez-MacGregor, M., Perlmutter, J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02309 · Cited by 1,574
Hoadley, K. A., Yau, C., Wolf, D. M., Cherniack, A. D., Tamborero, D., Ng, S., Leiserson, M. D. M., Niu, B., McLellan, M. D., Uzunangelov, V., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.049 · Cited by 1,499
Wolff, A. C., Hammond, M. E. H., Allison, K. H., Harvey, B. E., Mangu, P. B., Bartlett, J. M. S., Bilous, M., Ellis, I. O., Fitzgibbons, P., Hanna, W., et al. (2018) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2018-0902-sa · Cited by 1,474
Clinical implications of the intrinsic molecular subtypes of breast cancer
Prat, A., Pineda, E., Adamo, B., Galván, P., Fernández, A., Gaba, L., Díez, M., Viladot, M., Arance, A., & Muñoz, M. (2015) · The Breast · doi:10.1016/j.breast.2015.07.008 · Cited by 1,319
The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers
Razavi, P., Chang, M. T., Xu, G., Bandlamudi, C., Ross, D. S., Vasan, N., Cai, Y., Bielski, C. M., Donoghue, M. T. A., Jonsson, P., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.08.008 · Cited by 996
Ross, J. S., & Fletcher, J. A. (1998) · STEM CELLS · doi:10.1002/stem.160413 · Cited by 985
Swain, S. M., Miles, D., Kim, S.-B., Im, Y.-H., Im, S.-A., Semiglazov, V., Ciruelos, E., Schneeweiss, A., Loi, S., Monturus, E., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30863-0 · Cited by 922
HER2-Low Breast Cancer: Pathological and Clinical Landscape
Tarantino, P., Hamilton, E., Tolaney, S. M., Cortes, J., Morganti, S., Ferraro, E., Marra, A., Viale, G., Trapani, D., Cardoso, F., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02488 · Cited by 791
Modi, S., Park, H., Murthy, R. K., Iwata, H., Tamura, K., Tsurutani, J., Moreno-Aspitia, A., Doi, T., Sagara, Y., Redfern, C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02318 · Cited by 787
Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
Schettini, F., Chic, N., Brasó-Maristany, F., Paré, L., Pascual, T., Conte, B., Martínez-Sáez, O., Adamo, B., Vidal, M., Barnadas, E., et al. (2021) · npj Breast Cancer · doi:10.1038/s41523-020-00208-2 · Cited by 670
Banerji, U., van Herpen, C. M. L., Saura, C., Thistlethwaite, F., Lord, S., Moreno, V., Macpherson, I. R., Boni, V., Rolfo, C., de Vries, E. G. E., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30328-6 · Cited by 547
Self-citationFehrenbacher, L., Cecchini, R. S., Geyer Jr, C. E., Rastogi, P., Costantino, J. P., Atkins, J. N., Crown, J. P., Polikoff, J., Boileau, J.-F., Provencher, L., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01455 · Cited by 404
Viani, G. A., Afonso, S. L., Stefano, E. J., De Fendi, L. I., & Soares, F. V. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-153 · Cited by 381
Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond
Marchiò, C., Annaratone, L., Marques, A., Casorzo, L., Berrino, E., & Sapino, A. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.02.016 · Cited by 377
Huo, D., Hu, H., Rhie, S. K., Gamazon, E. R., Cherniack, A. D., Liu, J., Yoshimatsu, T. F., Pitt, J. J., Hoadley, K. A., Troester, M., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0595 · Cited by 283
Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer
Cejalvo, J. M., Martínez de Dueñas, E., Galván, P., García-Recio, S., Burgués Gasión, O., Paré, L., Antolín, S., Martinello, R., Blancas, I., Adamo, B., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2717 · Cited by 245
Prat, A., Carey, L. A., Adamo, B., Vidal, M., Tabernero, J., Cortés, J., Parker, J. S., Perou, C. M., & Baselga, J. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju152 · Cited by 233
HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer
Rinnerthaler, G., Gampenrieder, S. P., & Greil, R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051115 · Cited by 220
Mittendorf, E. A., Lu, B., Melisko, M., Price Hiller, J., Bondarenko, I., Brunt, A. M., Sergii, G., Petrakova, K., & Peoples, G. E. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2867 · Cited by 212
Mendes, D., Alves, C., Afonso, N., Cardoso, F., Passos-Coelho, J. L., Costa, L., Andrade, S., & Batel-Marques, F. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0648-2 · Cited by 187
Prat, A., Pascual, T., De Angelis, C., Gutierrez, C., Llombart-Cussac, A., Wang, T., Cortés, J., Rexer, B., Paré, L., Forero, A., et al. (2020) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djz042 · Cited by 175
Prat, A., Chaudhury, A., Solovieff, N., Paré, L., Martinez, D., Chic, N., Martínez‐Sáez, O., Brasó‐Maristany, F., Lteif, A., Taran, T., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02977 · Cited by 164
The Exciting New Field of HER2-Low Breast Cancer Treatment
Eiger, D., Agostinetto, E., Saúde-Conde, R., & de Azambuja, E. (2021) · Cancers · doi:10.3390/cancers13051015 · Cited by 160
Self-citationFumagalli, D., Venet, D., Ignatiadis, M., Azim, H. A., Maetens, M., Rothé, F., Salgado, R., Bradbury, I., Pusztai, L., Harbeck, N., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3824 · Cited by 150
Self-citationRossi, V., Sarotto, I., Maggiorotto, F., Berchialla, P., Kubatzki, F., Cont, N. T., Redana, S., Martinello, R., Valabrega, G., Aglietta, M., et al. (2012) · The Oncologist · doi:10.1634/theoncologist.2012-0194 · Cited by 136
Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer
Eggemann, H., Ignatov, T., Burger, E., Kantelhardt, E. J., Fettke, F., Thomssen, C., Costa, S. D., & Ignatov, A. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0335 · Cited by 117
Clifton, G. T., Hale, D. F., Vreeland, T. J., Hickerson, A. T., Litton, J. K., Alatrash, G., Murthy, R. K., Qiao, N., Philips, A. V., Lukas, J. J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2741 · Cited by 103
ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer
Pinhel, I. F., Hills, M., Drury, S., Salter, J., Sumo, G., A’Hern, R., Bliss, J. M., Šestak, I., Cuzick, J. M., Barrett-Lee, P. J., et al. (2012) · Breast Cancer Research · doi:10.1186/bcr3145 · Cited by 67
Griguolo, G., Brasó‐Maristany, F., González‐Farré, B., Pascual, T., Chic, N., Saurí, T., Kates, R. E., Gluz, O., Martínez, D., Paré, L., et al. (2020) · Cancers · doi:10.3390/cancers12071902 · Cited by 56
Breast Cancer Heterogeneity in Primary and Metastatic Disease
Kalinowski, L., Saunus, J. M., Reed, A. E. M., & Lakhani, S. R. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-20301-6_6 · Cited by 50
Targeting the Human Epidermal Growth Factor Receptor Family in Breast Cancer beyond HER2
Riecke, K., & Witzel, I. (2020) · Breast Care · doi:10.1159/000510998 · Cited by 20
Cited by
Tarantino, P., Viale, G., Press, M. F., Hu, X., Penault-Llorca, F., Bardia, A., Batistatou, A., Burstein, H. J., Carey, L. A., Cortes, J., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.05.008 · Cited by 312
Metadata
- Authors
- Agostinetto, E., Rediti, M., Fimereli, D., Debien, V., Piccart, M., Aftimos, P., Sotiriou, C., & de Azambuja, E.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2021-06-05
- Volume
- 13
- Issue
- 11
- Pages
- 2824
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W3166066183
- Cited by
- 267
- References
- 39
- FWCI
- 16.50
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.